SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas selection for a U.S. Army program to develop ultra-high-voltage silicon-carbide devices has drawn attention as a technology-validation and domestic-manufacturing milestone, with traders also speculating about future defense and AI-infrastructure applications. The reaction is divided: some see long-term potential, while others note it is a prototype effort with no disclosed financial terms or immediate revenue, and debate the stocks volatile moves.

London-based Quant Network is set to revolutionise blockchain technology with the development of their blockchain operating system Overledger. The experienced team are determined to fulfil the original vision of the internet by creating an open trusted network for people, machines, and data to operate securely and safely.  Overledger -the first interoperable blockchain operating system that facilitates internet-scale development of decentralised, multi-chain applications. Overledger has the ability to unlock and distribute value and applications across current and future blockchains. It is an agnostic platform that connects the world's networks to blockchains and ensures you're not limited to any single a vendor or technology. Overledger is the only platform that facilitates the development of internet-scales development of decentralised, multi-chain applications.

Quant

Quants selection by The Clearing House to support its on-chain money initiative is driving attention, with traders framing the banking and tokenized-deposit project as a major adoption catalyst. The sharp rally has prompted enthusiastic accumulation and scarcity claims, alongside profit-taking and skepticism about whether the partnership will create meaningful demand for the QNT token, given the networks planned rollout is still ahead.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

AstraZenecas strategic investment in Summit and planned ivonescimab combination trials are driving attention, with traders welcoming the added financial backing and pharma validation. Some speculate it could lead to a buyout or short squeeze, while others caution that it is an equity investmentnot an acquisitionand does not resolve the drugs FDA approval risk.

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.

Kodiak Sciences Inc

Kodiaks shares surged after Zenkuda and KSI-501 met primary endpoints in the Phase 3 DAYBREAK trial for wet AMD, with traders focusing on Zenkudas potential for longer dosing intervals and a planned FDA filing. The rally has sparked bullish short-squeeze chatter, while skeptics question the drugs edge over established treatments and warn about valuation, financing needs, and possible dilution.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

XERS is drawing attention after a sharp run toward the $10 level, with traders pointing to heavy late-day buying and accumulation but no confirmed new catalyst. Bullish discussion centers on Recorlevs growth and XP-8121s Phase 3 potential, while buyout and major-deal talk remains speculation and some traders question the long development timeline.

Canadian Solar, Inc. engages in the manufacture of solar photovoltaic modules, provision of solar energy and battery storage solutions, and development of utility-scale solar and battery storage products. It operates through the CSI Solar and Global Energy segments. The CSI Solar segment designs, develops, and manufactures solar ingots, wafers, cells, modules, and other solar power and battery storage products. The Global Energy segment includes solar and battery storage project development and sale, asset management services for operational projects, sale of electricity, and investment in retained assets. The company was founded by Shawn Qu in October 2001 and is headquartered in Kitchener, Canada.

Canadian Solar Inc

Canadian Solars weak Q2 results and cautious outlook are weighing on the shares, with traders pointing to ongoing losses, lower revenue and pressure from the U.S. factory ramp. Bulls argue that U.S. manufacturing, storage growth and project monetizations could improve the longer-term picture, while some community claims that heavy shorting is driving the decline remain unverified speculation.

NANO Nuclear Energy, Inc. is a microreactor and nuclear technology company, which provides supply energy services. Its products in technical development are ZEUS, a solid core battery reactor, and ODIN, a low-pressure coolant reactor. The company is founded by Jiang Yu in February, 2022 and is headquartered in New York, NY.

Nano Nuclear Energy Inc.

Needhams initiation of coverage with a Buy rating is drawing attention, with traders citing the companys licensing progress and financial runway. The optimism is tempered by continued weakness in nuclear stocks and concerns about NNEs execution risks and early-stage commercialization.

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

AVAXs sharp rally and rising volume have fueled talk of an altcoin rotation, with traders also pointing to tokenization and institutional-adoption prospectsincluding reported interest in Avalanche for tokenized securities. Bulls see the move as a breakout tied to real-world-asset use cases, while skeptics call it speculative and warn that gains may fade.

The Goldman Sachs Group, Inc. engages in the provision of financial services. It operates through the following business segments: Global Banking and Markets, Asset and Wealth Management, and Platform Solutions. The Global Banking and Markets segment includes investment banking, global investments, and equity and debt investments. The Asset and Wealth Management segment relates to the direct-to-consumer banking business which includes lending, deposit-taking, and investing. The Platform Solutions segment includes consumer platforms such as partnerships offering credit cards and point-of-sale financing, and transaction banking. The company was founded by Marcus Goldman in 1869 and is headquartered in New York, NY.

Goldman Sachs Group, Inc.

Goldman shares are drawing attention amid a sharp pullback and weakness across major banks, which traders link to rate and yield-curve concerns and a softer near-term capital-markets outlook. Some see the decline as an attractive dip ahead of earnings, while others worry that selling pressure and weaker trading or deal activity could persist.

Spdr Dow Jones Industrial Average ETF Trust - Spdr Dow Jones Industrial Average ETF Trust

DIA is drawing attention amid a broad-market pullback as rising Treasury yields and elevated oil prices tied to the Iran conflict stoke concerns about inflation and further Fed tightening. Traders are divided between warnings of more downside and views that the dip may offer a buying opportunity or reverse.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


Jwex2012

Printed in English